1-2 of 2
Dima El-Sharkawi
Close
Sort by
Journal Articles

Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study

Clinical Trials & Observations
Marco Herling, Claire Dearden, Francesco Zaja, Dima El-Sharkawi, Wei Ding, Mar Bellido, Amit Khot, Lidwine Tick, Eric Jacobsen, Toby A. Eyre, Damien Roos-Weil, Tapan Kadia, Elisa Lucchini, Natali Pflug, Matthew S. Davids, German Pena, Nabanita Mukherjee, Mohamed Badawi, Tamas Vizkelety, Philipp B. Staber
Journal: Blood Advances
Blood Adv (2024) 8 (4): 842–845.
https://doi.org/10.1182/bloodadvances.2023012248
Published: 2024
Includes: Supplemental data
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data